Free from Publisher

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

S Suissa, S Dell'Aniello, P Ernst - European Respiratory …, 2017 - Eur Respiratory Soc
The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
被引用次数：79 相关文章

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events.

S Suissa, S Dell'Aniello, P Ernst - The European Respiratory …, 2017 - europepmc.org
The cardiovascular risk of concurrently using long-acting β 2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

S Suissa, S Dell'Aniello, P Ernst - The European …, 2017 - pubmed.ncbi.nlm.nih.gov
The cardiovascular risk of concurrently using long-acting β 2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

S Suissa, S Dell'Aniello, P Ernst - European Respiratory Journal, 2017 - cir.nii.ac.jp
抄録< jats: p> The cardiovascular risk of concurrently using long-acting β< jats: sub> 2</jats:
sub>-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed …